Aikou Okamoto

50PUBLICATIONS
300CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersGeriatrics and gerontologyOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Oct 24, 2026
Impact of platinum-free interval on the efficacy of lenvatinib plus pembrolizumab in advanced or recurrent endometrial cancer.

|Oct 09, 2026
Cabergoline Suppresses FSH-Induced Differentiation and Steroidogenesis in Primary Cultured Rat Granulosa Cells.

|Sep 26, 2026
Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology.

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Aug 07, 2026
Real-world safety and effectiveness of olaparib maintenance after first-relapse platinum-sensitive ovarian cancer in Japan: a multicenter historical cohort (JGOG3026).

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

Pageof 9

Frequent Collaborators

11 joint publications

Hiroshi Tanabe

11 joint publications

Hirokuni Takano

10 joint publications

Takayuki Enomoto

10 joint publications

Kazuhiro Takehara